Classification of GBA1 variants and their impact on Parkinson’s disease: an in silico score analysis

Abstract Bi-allelic pathogenic GBA1 variants cause Gaucher disease (GD), whereas certain heterozygous missense variants increase the risk of Parkinson’s disease (PD), although the underlying mechanisms are unclear. Here, we classified GBA1 missense variants using predictive and structural scores, an...

Full description

Saved in:
Bibliographic Details
Main Authors: Aymeric Lanore, Christelle Tesson, Aymeric Basset, François-Xavier Lejeune, Guillaume Cogan, Graziella Mangone, Sara Sambin, Nathalie Bertille, Mathieu Anheim, Isabelle Arnulf, Solène Ansquer, Jean-Philippe Brandel, Christine Brefel-Courbon, Luc Defebvre, Sophie Drapier, Alexandre Eusebsio, Margherita Fabbri, Caroline Giordana, Elodie Hainque, Stephane Lehericy, Ana Marques, Caroline Moreau, Elena Moro, Fabienne Ory, Anne-Sophie Rolland, Stéphane Thobois, Marie Vidailhet, David Devos, Louise-Laure Mariani, Suzanne Lesage, Alexis Brice, Jean-Christophe Corvol, for the Predistim study group, the Iceberg study group, the NSPark study group
Format: Article
Language:English
Published: Nature Portfolio 2025-08-01
Series:npj Parkinson's Disease
Online Access:https://doi.org/10.1038/s41531-025-01060-6
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849332967455850496
author Aymeric Lanore
Christelle Tesson
Aymeric Basset
François-Xavier Lejeune
Guillaume Cogan
Graziella Mangone
Sara Sambin
Nathalie Bertille
Mathieu Anheim
Isabelle Arnulf
Solène Ansquer
Jean-Philippe Brandel
Christine Brefel-Courbon
Luc Defebvre
Sophie Drapier
Alexandre Eusebsio
Margherita Fabbri
Caroline Giordana
Elodie Hainque
Stephane Lehericy
Ana Marques
Caroline Moreau
Elena Moro
Fabienne Ory
Anne-Sophie Rolland
Stéphane Thobois
Marie Vidailhet
David Devos
Louise-Laure Mariani
Suzanne Lesage
Alexis Brice
Jean-Christophe Corvol
for the Predistim study group
the Iceberg study group
the NSPark study group
author_facet Aymeric Lanore
Christelle Tesson
Aymeric Basset
François-Xavier Lejeune
Guillaume Cogan
Graziella Mangone
Sara Sambin
Nathalie Bertille
Mathieu Anheim
Isabelle Arnulf
Solène Ansquer
Jean-Philippe Brandel
Christine Brefel-Courbon
Luc Defebvre
Sophie Drapier
Alexandre Eusebsio
Margherita Fabbri
Caroline Giordana
Elodie Hainque
Stephane Lehericy
Ana Marques
Caroline Moreau
Elena Moro
Fabienne Ory
Anne-Sophie Rolland
Stéphane Thobois
Marie Vidailhet
David Devos
Louise-Laure Mariani
Suzanne Lesage
Alexis Brice
Jean-Christophe Corvol
for the Predistim study group
the Iceberg study group
the NSPark study group
author_sort Aymeric Lanore
collection DOAJ
description Abstract Bi-allelic pathogenic GBA1 variants cause Gaucher disease (GD), whereas certain heterozygous missense variants increase the risk of Parkinson’s disease (PD), although the underlying mechanisms are unclear. Here, we classified GBA1 missense variants using predictive and structural scores, and analysed their associations with enzyme activity, Saposin C (SapC) interaction and PD progression in 639 patients with heterozygous GBA1 variants from five cohorts. Principal component analysis (PCA) identified two components: PC1, associated with reduced β-glucocerebosidase activity, the GD clinical severity classification, younger age at PD diagnosis, and faster cognitive and motor decline; and PC2, associated with surface-exposed, flexible regions involved in SapC interactions, younger age at PD diagnosis, and slightly with motor decline. These findings highlight that impaired SapC interactions, in addition to reduced activity, may contribute to PD severity in GBA1 variant carriers. This is relevant for therapeutic approaches aimed at stabilizing β-glucocerebosidase or enhancing its enzymatic activity in PD.
format Article
id doaj-art-3053b5253a2c43a08d2ff646cfbb962a
institution Kabale University
issn 2373-8057
language English
publishDate 2025-08-01
publisher Nature Portfolio
record_format Article
series npj Parkinson's Disease
spelling doaj-art-3053b5253a2c43a08d2ff646cfbb962a2025-08-20T03:46:03ZengNature Portfolionpj Parkinson's Disease2373-80572025-08-0111111410.1038/s41531-025-01060-6Classification of GBA1 variants and their impact on Parkinson’s disease: an in silico score analysisAymeric Lanore0Christelle Tesson1Aymeric Basset2François-Xavier Lejeune3Guillaume Cogan4Graziella Mangone5Sara Sambin6Nathalie Bertille7Mathieu Anheim8Isabelle Arnulf9Solène Ansquer10Jean-Philippe Brandel11Christine Brefel-Courbon12Luc Defebvre13Sophie Drapier14Alexandre Eusebsio15Margherita Fabbri16Caroline Giordana17Elodie Hainque18Stephane Lehericy19Ana Marques20Caroline Moreau21Elena Moro22Fabienne Ory23Anne-Sophie Rolland24Stéphane Thobois25Marie Vidailhet26David Devos27Louise-Laure Mariani28Suzanne Lesage29Alexis Brice30Jean-Christophe Corvol31for the Predistim study groupthe Iceberg study groupthe NSPark study groupSorbonne Université, Institut du Cerveau – Paris Brain Institute – ICM, Inserm, CNRS, Assistance Publique Hôpitaux de Paris, NS-Park/FCRIN network, Department of Neurology, CIC Neurosciences, Hôpital Pitié-SalpêtrièreSorbonne Université, Institut du Cerveau – Paris Brain Institute – ICM, Inserm, CNRS, Assistance Publique Hôpitaux de Paris, NS-Park/FCRIN network, Department of Neurology, CIC Neurosciences, Hôpital Pitié-SalpêtrièreSorbonne Université, Institut du Cerveau – Paris Brain Institute – ICM, Inserm, CNRS, Assistance Publique Hôpitaux de Paris, NS-Park/FCRIN network, Department of Neurology, CIC Neurosciences, Hôpital Pitié-SalpêtrièreSorbonne Université, Institut du Cerveau – Paris Brain Institute – ICM, Inserm, CNRS, Assistance Publique Hôpitaux de Paris, NS-Park/FCRIN network, Department of Neurology, CIC Neurosciences, Hôpital Pitié-SalpêtrièreSorbonne Université, Institut du Cerveau – Paris Brain Institute – ICM, Inserm, CNRS, Assistance Publique Hôpitaux de Paris, NS-Park/FCRIN network, Department of Neurology, CIC Neurosciences, Hôpital Pitié-SalpêtrièreSorbonne Université, Institut du Cerveau – Paris Brain Institute – ICM, Inserm, CNRS, Assistance Publique Hôpitaux de Paris, NS-Park/FCRIN network, Department of Neurology, CIC Neurosciences, Hôpital Pitié-SalpêtrièreSorbonne Université, Institut du Cerveau – Paris Brain Institute – ICM, Inserm, CNRS, Assistance Publique Hôpitaux de Paris, NS-Park/FCRIN network, Department of Neurology, CIC Neurosciences, Hôpital Pitié-SalpêtrièreAP-HP, Hôpital Pitié Salpêtrière, Centre de Pharmacoépidémiologie (Cephepi), CIC-1901Department of Neurology, Neurogenetic Reference Centre, Parkinson’s Expert Centre, University Hospitals of StrasbourgSorbonne Université, Institut du Cerveau – Paris Brain Institute – ICM, Inserm, CNRS, Assistance Publique Hôpitaux de Paris, NS-Park/FCRIN network, Department of Neurology, CIC Neurosciences, Hôpital Pitié-SalpêtrièreNeurology Department, Centre Expert Parkinson, CIC-INSERM 1402, CHU PoitiersHôpital Fondation Ophtalmologique A de Rothschild, Unité James Parkisnon, NS-PARK/FCRIN NetworkClinical Investigation Center CIC1436, Parkinson Expert Center, Department of Clinical, Pharmacology and Neuroscience, NS-Park/FCRIN network, NeuroToul COEN Center; Toulouse, University Hospital, INSERM and University of Toulouse 3Parkinson’s Disease Center of Excellence, Department of Neurology, University of Lille, CHU Lille, INSERM U1172- Degenerative & Vascular Cognitive DisordersPontchaillou University Hospital, Department of Neurology, CIC INSERM 1414Aix Marseille Université, AP-HM, Hôpital de La Timone, Service de Neurologie et Pathologie du MouvementClinical Investigation Center CIC1436, Parkinson Expert Center, Department of Clinical, Pharmacology and Neuroscience, NS-Park/FCRIN network, NeuroToul COEN Center; Toulouse, University Hospital, INSERM and University of Toulouse 3Neurology Department, NS-Park/FCRIN network, Centre Hospitalier Universitaire de Nice, Université Côte d’AzurSorbonne Université, Institut du Cerveau – Paris Brain Institute – ICM, Inserm, CNRS, Assistance Publique Hôpitaux de Paris, NS-Park/FCRIN network, Department of Neurology, CIC Neurosciences, Hôpital Pitié-SalpêtrièreAssistance Publique Hôpitaux de Paris, Department of Neuroradiology, Hôpital Pitié-SalpêtrièreUniversité Clermont Auvergne, IGCNC, Department of Neurology, Parkinson expert center, CHU Clermont-FerrandParkinson’s Disease Center of Excellence, Department of Neurology, University of Lille, CHU Lille, INSERM U1172- Degenerative & Vascular Cognitive DisordersGrenoble Alpes University, Movement Disorders Unit, Division of Neurology, CHU de Grenoble, Grenoble Institute of NeurosciencesClinical Investigation Center CIC1436, Parkinson Expert Center, Department of Clinical, Pharmacology and Neuroscience, NS-Park/FCRIN network, NeuroToul COEN Center; Toulouse, University Hospital, INSERM and University of Toulouse 3Department of Medical Pharmacology, CHU Lille, University of Lille, Lille Neuroscience & Cognition, INSERM, UMR-S1172, LICEND, NS-Park/F-CRIN networkHospices Civils de Lyon, Hôpital Neurologique Pierre Wertheimer, Department of Neurology C, NS-Park/FCRIN network, Univ Lyon, Université Claude Bernard Lyon 1, Faculté de Médecine Lyon Sud Charles Mérieux, Lyon, France; INSERM, Centre de Recherche en Neurosciences de Lyon, PATH-PARKSorbonne Université, Institut du Cerveau – Paris Brain Institute – ICM, Inserm, CNRS, Assistance Publique Hôpitaux de Paris, NS-Park/FCRIN network, Department of Neurology, CIC Neurosciences, Hôpital Pitié-SalpêtrièreDepartment of Medical Pharmacology, CHU Lille, University of Lille, Lille Neuroscience & Cognition, INSERM, UMR-S1172, LICEND, NS-Park/F-CRIN networkSorbonne Université, Institut du Cerveau – Paris Brain Institute – ICM, Inserm, CNRS, Assistance Publique Hôpitaux de Paris, NS-Park/FCRIN network, Department of Neurology, CIC Neurosciences, Hôpital Pitié-SalpêtrièreSorbonne Université, Institut du Cerveau – Paris Brain Institute – ICM, Inserm, CNRS, Assistance Publique Hôpitaux de Paris, NS-Park/FCRIN network, Department of Neurology, CIC Neurosciences, Hôpital Pitié-SalpêtrièreSorbonne Université, Institut du Cerveau – Paris Brain Institute – ICM, Inserm, CNRS, Assistance Publique Hôpitaux de Paris, NS-Park/FCRIN network, Department of Neurology, CIC Neurosciences, Hôpital Pitié-SalpêtrièreSorbonne Université, Institut du Cerveau – Paris Brain Institute – ICM, Inserm, CNRS, Assistance Publique Hôpitaux de Paris, NS-Park/FCRIN network, Department of Neurology, CIC Neurosciences, Hôpital Pitié-SalpêtrièreAbstract Bi-allelic pathogenic GBA1 variants cause Gaucher disease (GD), whereas certain heterozygous missense variants increase the risk of Parkinson’s disease (PD), although the underlying mechanisms are unclear. Here, we classified GBA1 missense variants using predictive and structural scores, and analysed their associations with enzyme activity, Saposin C (SapC) interaction and PD progression in 639 patients with heterozygous GBA1 variants from five cohorts. Principal component analysis (PCA) identified two components: PC1, associated with reduced β-glucocerebosidase activity, the GD clinical severity classification, younger age at PD diagnosis, and faster cognitive and motor decline; and PC2, associated with surface-exposed, flexible regions involved in SapC interactions, younger age at PD diagnosis, and slightly with motor decline. These findings highlight that impaired SapC interactions, in addition to reduced activity, may contribute to PD severity in GBA1 variant carriers. This is relevant for therapeutic approaches aimed at stabilizing β-glucocerebosidase or enhancing its enzymatic activity in PD.https://doi.org/10.1038/s41531-025-01060-6
spellingShingle Aymeric Lanore
Christelle Tesson
Aymeric Basset
François-Xavier Lejeune
Guillaume Cogan
Graziella Mangone
Sara Sambin
Nathalie Bertille
Mathieu Anheim
Isabelle Arnulf
Solène Ansquer
Jean-Philippe Brandel
Christine Brefel-Courbon
Luc Defebvre
Sophie Drapier
Alexandre Eusebsio
Margherita Fabbri
Caroline Giordana
Elodie Hainque
Stephane Lehericy
Ana Marques
Caroline Moreau
Elena Moro
Fabienne Ory
Anne-Sophie Rolland
Stéphane Thobois
Marie Vidailhet
David Devos
Louise-Laure Mariani
Suzanne Lesage
Alexis Brice
Jean-Christophe Corvol
for the Predistim study group
the Iceberg study group
the NSPark study group
Classification of GBA1 variants and their impact on Parkinson’s disease: an in silico score analysis
npj Parkinson's Disease
title Classification of GBA1 variants and their impact on Parkinson’s disease: an in silico score analysis
title_full Classification of GBA1 variants and their impact on Parkinson’s disease: an in silico score analysis
title_fullStr Classification of GBA1 variants and their impact on Parkinson’s disease: an in silico score analysis
title_full_unstemmed Classification of GBA1 variants and their impact on Parkinson’s disease: an in silico score analysis
title_short Classification of GBA1 variants and their impact on Parkinson’s disease: an in silico score analysis
title_sort classification of gba1 variants and their impact on parkinson s disease an in silico score analysis
url https://doi.org/10.1038/s41531-025-01060-6
work_keys_str_mv AT aymericlanore classificationofgba1variantsandtheirimpactonparkinsonsdiseaseaninsilicoscoreanalysis
AT christelletesson classificationofgba1variantsandtheirimpactonparkinsonsdiseaseaninsilicoscoreanalysis
AT aymericbasset classificationofgba1variantsandtheirimpactonparkinsonsdiseaseaninsilicoscoreanalysis
AT francoisxavierlejeune classificationofgba1variantsandtheirimpactonparkinsonsdiseaseaninsilicoscoreanalysis
AT guillaumecogan classificationofgba1variantsandtheirimpactonparkinsonsdiseaseaninsilicoscoreanalysis
AT graziellamangone classificationofgba1variantsandtheirimpactonparkinsonsdiseaseaninsilicoscoreanalysis
AT sarasambin classificationofgba1variantsandtheirimpactonparkinsonsdiseaseaninsilicoscoreanalysis
AT nathaliebertille classificationofgba1variantsandtheirimpactonparkinsonsdiseaseaninsilicoscoreanalysis
AT mathieuanheim classificationofgba1variantsandtheirimpactonparkinsonsdiseaseaninsilicoscoreanalysis
AT isabellearnulf classificationofgba1variantsandtheirimpactonparkinsonsdiseaseaninsilicoscoreanalysis
AT soleneansquer classificationofgba1variantsandtheirimpactonparkinsonsdiseaseaninsilicoscoreanalysis
AT jeanphilippebrandel classificationofgba1variantsandtheirimpactonparkinsonsdiseaseaninsilicoscoreanalysis
AT christinebrefelcourbon classificationofgba1variantsandtheirimpactonparkinsonsdiseaseaninsilicoscoreanalysis
AT lucdefebvre classificationofgba1variantsandtheirimpactonparkinsonsdiseaseaninsilicoscoreanalysis
AT sophiedrapier classificationofgba1variantsandtheirimpactonparkinsonsdiseaseaninsilicoscoreanalysis
AT alexandreeusebsio classificationofgba1variantsandtheirimpactonparkinsonsdiseaseaninsilicoscoreanalysis
AT margheritafabbri classificationofgba1variantsandtheirimpactonparkinsonsdiseaseaninsilicoscoreanalysis
AT carolinegiordana classificationofgba1variantsandtheirimpactonparkinsonsdiseaseaninsilicoscoreanalysis
AT elodiehainque classificationofgba1variantsandtheirimpactonparkinsonsdiseaseaninsilicoscoreanalysis
AT stephanelehericy classificationofgba1variantsandtheirimpactonparkinsonsdiseaseaninsilicoscoreanalysis
AT anamarques classificationofgba1variantsandtheirimpactonparkinsonsdiseaseaninsilicoscoreanalysis
AT carolinemoreau classificationofgba1variantsandtheirimpactonparkinsonsdiseaseaninsilicoscoreanalysis
AT elenamoro classificationofgba1variantsandtheirimpactonparkinsonsdiseaseaninsilicoscoreanalysis
AT fabienneory classificationofgba1variantsandtheirimpactonparkinsonsdiseaseaninsilicoscoreanalysis
AT annesophierolland classificationofgba1variantsandtheirimpactonparkinsonsdiseaseaninsilicoscoreanalysis
AT stephanethobois classificationofgba1variantsandtheirimpactonparkinsonsdiseaseaninsilicoscoreanalysis
AT marievidailhet classificationofgba1variantsandtheirimpactonparkinsonsdiseaseaninsilicoscoreanalysis
AT daviddevos classificationofgba1variantsandtheirimpactonparkinsonsdiseaseaninsilicoscoreanalysis
AT louiselauremariani classificationofgba1variantsandtheirimpactonparkinsonsdiseaseaninsilicoscoreanalysis
AT suzannelesage classificationofgba1variantsandtheirimpactonparkinsonsdiseaseaninsilicoscoreanalysis
AT alexisbrice classificationofgba1variantsandtheirimpactonparkinsonsdiseaseaninsilicoscoreanalysis
AT jeanchristophecorvol classificationofgba1variantsandtheirimpactonparkinsonsdiseaseaninsilicoscoreanalysis
AT forthepredistimstudygroup classificationofgba1variantsandtheirimpactonparkinsonsdiseaseaninsilicoscoreanalysis
AT theicebergstudygroup classificationofgba1variantsandtheirimpactonparkinsonsdiseaseaninsilicoscoreanalysis
AT thensparkstudygroup classificationofgba1variantsandtheirimpactonparkinsonsdiseaseaninsilicoscoreanalysis